When was Vemurafenib launched?

Vemurafenib( Vemurafenib)On20118menstruation United StatesFDA< /span>It was approved for marketing on 2017 year7 month29 by the State Food and Drug Administration of China. Vemurafenib is a kinase inhibitor indicated for the treatment of patients with Erdheim-Chester disease who have the BRAF V600 mutation and melanoma who have the BRAF V600E mutation.

Vemurafenibis a competitive kinase inhibitor that is active against mutated BRAF kinases such as V600E. It exerts its function by binding to the ATP binding domain of mutated BRAF. Vemurafenib was jointly developed by Roche and Plexxikon and launched in 2011 on August 17, 2017 by Hoffmann-La Roche. Following the approval, Roche launched an extensive development program in partnership with Genentech.

Since 2011, vemurafenib has been approved for the treatment of metastatic melanoma, located in exon 15codonBRAF mutation at n>600 was named V600E. The 3 V600E mutation, a glutamic acid substitution of valine, accounts for 54% of cutaneous melanoma cases. Vemurafenib's approval was extended in 2017. For the treatment of adult patients with Erdheim-Chester disease whose cancer cells harbor the BRAF V600 mutation. Erdheim-Chester disease is an extremely rare histiocytic disorder that affects the large bones, large blood vessels, central nervous system, as well as the skin and lungs. It has been reported that Erdheim-Chester disease is associated with the V600E mutation. The Turkish version of the original medicine costs more than 2,000 per box.2 If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.